SOME ASPECTS OF INDIRECT BURDEN OF BRONCHIAL ASTHMA
Abstract
The aim of the research is the analysis of the structure of indirect expenses at the treatment of patients with bronchial asthma with uncontrolled clinical course. 306 outpatients’ cards and disease histories of patients who were at the outpatient’s treatment in the Far-Eastern Scientific Center of Physiology and Pathology of Respiration of the Siberian Branch of Russian Academy of Medical Sciences from 2007 till 2010 were studied. It was found out that the quantity of days of patients’ incapacity for work depends on the basis therapy. The use of Seretide® medication in the complex therapy leads to the largest decrease of the period of temporary incapacity for work in comparison with other analogous medications, which results in the lowering of temporal incapacity medical certificates expenses and as a consequence to the decrease of the loss of gross regional product.
About the Authors
Natal'ya V. Avdeeva
Far Eastern Scientific Center of Physiology and Pathology of Respiration of Siberian Branch RAMS; Amur State Medical Academy
Russian Federation
Russian Federation
Elena V. Polyanskaya
Far Eastern Scientific Center of Physiology and Pathology of Respiration SB RAMS
Russian Federation
Russian Federation
References
1. Авдеева Н.В., Приходько А.Г. Стоимость стационарного лечения бронхиальной астмы у больных с холодовой гиперреактивностью дыхательных путей // Бюл. физиол. и патол. дыхания. 2010. Вып.38. С.33–36.
2. Фармакоэкономический анализ эффективности лечения бронхиальной астмы тяжелой степени комбинированными глюкокортикостероидами / Г.Л.Игнатова [и др.] // Пульмонология. 2008. №1. С.81–86.
3. Рудакова А.В. Фармакоэкономические аспекты комбинированной терапии бронхиальной астмы // Фармакоэкономика. 2010. Т.3, №1. С.47–51.
4. Особенности методологии фармакоэкономических исследований в условиях здравоохранения Российской Федерации (обзор публикаций за период с 1995 по 2007 гг.) / Р.И.Ягудина [и др.] // Фармакоэкономика. 2009. Т.2, №1. С.3–6.
5. Оптимизация поддерживающей терапии с использованием фармакоэкономической модели бронхиальной астмы (ОПТИМА) / Р.И.Ягудина [и др.] // Фармакоэкономика. 2010. Т.3, №1. С.40–46.
6. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2010. URL: http://www.ginasthma.org.
7. Avdeeva N.V., Prikhod’ko А.G. Bûlleten' fiziologii i patologii dyhaniyâ 2010; 38:33–36.
8. Ignatova G.L., Gabbasova L.A., Yanina L.I., Shukhovtsev M.I. Pul'monologiya 2008; 1:81–86.
9. Rudakova A.V. Farmakoekonomika 2010; 3(1):47–51.
10. Yagudina R.I., Kulikov A.Yu., Krysanov I.S., Litvinenko M.M., Morozov A.L. Farmakoekonomika 2009; 2(1):3–6.
11. Yagudina R.I., Kulikov A.Yu., Ogorodova L.M., Demko I.V., Tolkushin A.G., Kobyakova O.S., Chuchalin A.G. Farmakoekonomika 2010; 3(1):40–46.
12. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2010. Available at: http://www.ginasthma.org.
Review
For citations:
Avdeeva N.V., Polyanskaya E.V. SOME ASPECTS OF INDIRECT BURDEN OF BRONCHIAL ASTHMA. Bulletin Physiology and Pathology of Respiration. 2012;(46):35-38. (In Russ.)
Views:
112
Email this article 